| Caprelsa (vandetanib) / Sanofi |
NCT00613054: Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma |
|
|
| Completed | 1 | 27 | US | Zactima, Gleevec, Hydroxyurea, Zactima-ZD6474-Vandetanib, Gleevec-Imatinib mesylate, Hydroxyurea-Droxia-Hydrea-Hydroxycarbamide | Annick Desjardins, Novartis Pharmaceuticals, AstraZeneca | Glioblastoma, Gliosarcoma | 03/09 | 04/09 | | |
IRUSZACT0073, NCT00822887: Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas |
|
|
| Completed | 1 | 13 | US | Vandetanib, ZD6474, Zactima, Fractionated Stereotactic Radiotherapy | University of Colorado, Denver, AstraZeneca | Malignant Gliomas | 05/10 | 01/11 | | |
NCT00613223: Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas |
|
|
| Completed | 1 | 49 | US | Vandetanib and Etoposide, Vandetanib - Zactima (ZD 6474), Etoposide - VP-16, Etopophos, Toposar, VePesid | Annick Desjardins, AstraZeneca | Gliosarcoma, Glioblastoma | 10/10 | 05/11 | | |
NCT00533169: ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma |
|
|
| Terminated | 1 | 10 | US | ZD6474, Zactima, Vandetanib, Retinoic Acid, Isotretinoin, Accutane, 13-cis-Retinoic Acid | M.D. Anderson Cancer Center, AstraZeneca | Neuroblastoma | 02/11 | 02/11 | | |
NCT00996723: Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) |
|
|
| Completed | 1 | 25 | US | vandetanib and dasatinib | St. Jude Children's Research Hospital, AstraZeneca, The Cure Starts Now Foundation, Tyler's Treehouse | Diffuse Intrinsic Pontine Glioma | 04/12 | 06/14 | | |
|
NCT00821080: Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma |
|
|
| Completed | 1 | 33 | US | Sirolimus, Vandetanib | Massachusetts General Hospital, Brigham and Women's Hospital, Dana-Farber Cancer Institute, AstraZeneca | Glioblastoma | 02/15 | 02/15 | | |
NCT01941849: Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma |
|
|
| Withdrawn | 1 | 0 | Europe | Vandetanib, Caprelsa, 131I-mIBG, Iodine-131 labelled Meta-iodobenzylguanine | University College, London, Cancer Research UK, AstraZeneca | Phaeochromocytoma, Paraganglioma | 12/15 | 12/15 | | |
